/SLS

Sellas Life Sciences Group Inc

SLS

$11.55USD↓-14.42%-1.95 today

MARKET CAP

2.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$11 – $14

52W RANGE

$1

$16

AI Summary

Stalk

TrimMedium

A decisive support failure below the 9/20/50 EMAs signals medium-term bearish acceleration despite a still-intact long-term uptrend above the 200 DMA. Oversold conditions warrant caution against chasing the decline, and under a Speculative mandate, the preferred approach is to defer short entry until a pullback into the broken support zone offers a clear rejection setup.

↑Galinpepimut-S (GPS) advancing toward Phase 3 readout with strong early efficacy data
↑$138.3 M cash and equivalents support late-stage trials through 2026
↓Q2 net loss widened to $9.6 M, R&D spend rose to $6.3 M

Full analysis →

Buying

9

institutions

Selling

0

institutions

New Positions

3

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	15.07 M	222.44 M	+2.87 M	+331.1%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	6.61 M	97.49 M	+1.72 M	+372.0%	0.01%
PA Perceptive Advisors LLC Q2 2026	BUYNEW	1.50 M	22.14 M	+1.50 M	+0.0%	0.33%
MM Millennium Management LLC Q2 2026	BUY	1.10 M	16.27 M	+100.48 K	+283.9%	0.01%
BA Balyasny Asset Management L.P. Q2 2026	BUY	500.00 K	7.38 M	+418.31 K	+2035.6%	0.01%
RT Renaissance Technologies LLC Q2 2026	BUYNEW	310.36 K	4.58 M	+310.36 K	+0.0%	0.01%
JC Jpmorgan Chase & Co Q2 2026	BUY	100.14 K	1.55 M	+18.31 K	+372.1%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	58.12 K	857.85 K	+4.13 K	+275.6%	0.00%
FC Farallon Capital Management LLC Q1 2026	BUYNEW	40.00 K	169.20 K	+40.00 K	+0.0%	0.00%